Recipharm announces signature of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273)

Recipharm, a leading contract development and manufacturing organisation (CDMO) announces that it has signed a letter of intent with Moderna, a U.S. based biotech company, to formulate, fill and finish mRNA-1273, Moderna’s COVID-19 vaccine candidate. The activity will be performed in Recipharm’s drug product manufacturing facility located in Monts, France. Recipharm has reserved capacity to support the anticipated demand for the vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.

Commenting on the announcement, Thomas Eldered, CEO of Recipharm said “We are delighted to be working with Moderna on this vital project in order to support the fight against COVID-19. Our operations in France are ideally suited to perform this work by combining our technical and operational knowhow to deliver high-quality pharmaceutical manufacture of biologics with a challenging timeline. We anticipate that the final agreement will be finalised during December”.
 

Contact information
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Jean-François Hilaire, Executive Vice President, telephone: +33 695 447 507
Tobias Hägglöv, CFO, ir@recipharm.com, telephone: +46 8 602 52 00 

This information is information that Recipharm AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on 24 November 2020 at 08:30 CET.

 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com